Qiagen (QGEN) said Thursday it intends to open a new facility in Esplugues de Llobregat in Spain in early 2026 and will move its QIAstat-Dx operations within the Barcelona area to the new site.
The new 8,000-square-meter facility will cover the entire value chain for the QIAstat-Dx system for syndromic testing to trace the cause of an illness in respiratory, gastrointestinal and meningitis/encephalitis, the company said.
Qiagen said the new facility will house its research & development, production, sales, marketing, quality assurance, and regulatory affairs teams.
The new site will also serve as a center of excellence for R&D in microfluidics, as well as system and assay development, the company said.
Price: 43.55, Change: -0.20, Percent Change: -0.46